oligofructose

Small moleculeexperimental

Fructooligosaccharides (FOS) also sometimes called oligofructose or oligofructan, are oligosaccharide fructans, used as an alternative sweetener. FOS exhibits sweetness levels between 30 and 50 percent of sugar in commercially prepared syrups. It occurs naturally, and its commercial use emerged in the 1980s in response to demand for healthier and calorie-reduced foods. — Wikipedia

Clinical trial activity

26 trials · 33 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
1

Earliest trial started Nov 1, 2005 (NCT00164099)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • Unspecified targetSupplementation

    supplementation

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • oligofructose

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07097389N/AJul 31, 2024University of Reading
NCT04578652Phase 3Oct 31, 2020University of Alberta
NCT04100200N/AOct 7, 2019Illinois Institute of Technology, United States Department of Agriculture
NCT04164914N/AApr 29, 2019Universidad Autonoma de Barcelona
NCT03482258N/AMay 31, 2018FrieslandCampina, University of Roehampton
NCT04250831N/AMar 12, 2018Roehampton University, University of Roehampton
NCT02642172N/AJan 1, 2016Hebrew University
NCT02628678N/ANov 1, 2015Kaleido Biosciences
NCT02569684N/AOct 1, 2015Norwegian Diabetes Association, Osaka University, University Hospital of North Norway
NCT02259465N/ASep 1, 2014University of London, University of Nottingham
NCT02232373N/AAug 1, 2014University of London, University of Nottingham
NCT02124759Phase 2Apr 1, 2014American Diabetes Association, University of Texas, San Antonio
NCT02127125Phase 2Apr 1, 2014American Diabetes Association, University of Texas, San Antonio
NCT02353403N/AJan 31, 2014Institut Pasteur, Tereos
NCT02352857N/AOct 31, 2013Institut Pasteur, Tereos
NCT01963364N/AOct 1, 2013University of Nottingham
NCT03517345N/AApr 22, 2013Istanbul University
NCT03184376N/AFeb 28, 2012University of Calgary
NCT01673152N/AFeb 1, 2012Medical University of Warsaw, Nutricia
NCT01304771Phase 1Dec 1, 2010Mayo Clinic, National Center for Complementary and Integrative Health (NCCIH)
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (33)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LondonAcademic/Hospital3112009
University of NottinghamAcademic/Hospital3312013
American Diabetes AssociationAcademic/Hospital2012014
Institut PasteurAcademic/Hospital2212013
TereosFor profit2012013
University of CalgaryAcademic/Hospital2212007
University of RoehamptonAcademic/Hospital2212018
University of Texas, San AntonioAcademic/Hospital2212014
AbecmaFor profit1012010
FrieslandCampinaFor profit1012018
Harvard UniversityAcademic/Hospital1112005
Hebrew UniversityAcademic/Hospital1112016
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012005
Illinois Institute of TechnologyAcademic/Hospital1112019
Istanbul UniversityAcademic/Hospital1112013
Kaleido BiosciencesFor profit1112015
Katholieke Universiteit LeuvenAcademic/Hospital1112006
Mayo ClinicAcademic/Hospital1112010
Medical University of WarsawAcademic/Hospital1112012
National Center for Complementary and Integrative Health (NCCIH)Government1012010
33 organizations
Page 1 / 2